Last updated: April 23, 2026
Indocyanine green (ICG) is supplied globally by specialty sterile-manufacturing and imaging-brand vendors, and by generic bulk-chemical producers for downstream sterile compounding or formulation. The most relevant supplier set depends on end use: (1) finished sterile ICG products for clinical use versus (2) bulk ICG for compounding/manufacturing.
Which suppliers provide indocyanine green as a finished product?
Finished ICG for clinical administration is typically marketed as an injectable solution under established brand and generic registrations. Supplier visibility is driven by country approvals, hospital distribution networks, and marketing authorization holders.
Finished-product channel (typical patterns)
- Brand-origin suppliers: Original R&D/brand holders or their regional affiliates distribute finished sterile ICG.
- Generic/in-market distributors: Local wholesalers sell registered ICG injection strengths and pack sizes under marketing authorization.
- Hospital procurement: Tender-driven purchasing often consolidates to a small set of distributors per geography.
What investors and R&D teams should map
- Marketing authorization holder (MAH) in the target country/region
- Responsible person and local distributor for tender supply reliability
- Sterile manufacturing site for quality and supply continuity
Which companies supply indocyanine green bulk for formulation or sterile compounding?
ICG bulk is offered by chemical suppliers that sell USP/EP-grade material or analytical-grade material for downstream processing. Bulk sources are commonly used for:
- sterile reconstitution products sold by branded/generic injectables,
- imaging-industry private labels,
- research-only manufacturing lots.
Common bulk supplier categories (by capability)
- Bulk chemical manufacturers (API-style production, CoA-driven supply)
- Specialty ingredient suppliers (regulated packaging, traceability, documentation support)
- Distribution of third-party bulk (repackaging with documentation)
How to screen indocyanine green suppliers for pharmaceutical compliance?
ICG supplier qualification should be built around documentation and manufacturing controls rather than catalog claims. Use a matrix focused on sterility, endotoxin, and traceability.
Supplier qualification checklist
- Quality system: GMP statement and batch traceability
- Sterility and pyrogen controls (for finished sterile product)
- Release documentation: CoA for each lot (assay, impurities, related substances)
- Specification alignment: USP/EP monograph compliance (as applicable)
- Stability data: for finished product shelf-life and storage
- Regulatory status: MAH and regulatory listing in target market
Critical attributes for ICG (practical)
- Assay and impurity profile (ICG degradation and related impurities)
- Particle control (for injection products)
- Osmolality and pH control (for injectable formulations, where relevant)
- Packaging and reconstitution compatibility (light sensitivity risk management)
What supply risks matter most for indocyanine green?
ICG supply can be concentrated due to:
- limited sterile manufacturing capacity,
- narrow formulation expertise,
- import dependency in certain countries.
Risk factors to watch
- Single-source regional distribution for the registered injection
- Lot-to-lot variation in dye purity affecting optical performance
- Regulatory re-listing delays after supplier changes
- Cold chain or protection requirements if stipulated by packaging and labeling
Supplier mapping framework (actionable for diligence)
The quickest way to build a decision-grade supplier map is to separate “finished sterile product” suppliers from “bulk chemical” suppliers, then overlay compliance proof.
1) Finished sterile product map
Create a table by country/region:
- MAH
- NDC (US) or local product code (where applicable)
- strengths (e.g., common clinical pack presentations)
- presentation (vial size, reconstitution details)
- distributor and hospital tender coverage
2) Bulk map
Create a table by lot documentation capability:
- grade offered (pharma/USP/EP vs analytical)
- documentation package (CoA, specification sheet, impurity listing)
- manufacturing origin site and GMP status
- lead time and safety stock flexibility
Representative supplier set: what the market typically includes
Because supplier availability depends on country listings and current distribution agreements, buyers should treat the following as categories to confirm against local regulatory databases and current tender catalogs:
- Sterile injectable ICG product suppliers through registered MAHs and hospital distributors
- Pharmaceutical-grade chemical suppliers that provide ICG bulk with GMP or documented controlled manufacturing
- Specialty imaging suppliers that distribute ICG for medical use and research use
Key Takeaways
- Indocyanine green sourcing splits into finished sterile injectable product suppliers (MAH/distributor-driven) and bulk chemical suppliers (ingredient-driven).
- Supplier diligence must center on GMP/CoA traceability, sterility/pyrogen controls for injectables, and impurity/assay specifications.
- Supply reliability depends on regional tender ecosystems and manufacturing concentration, so map MAHs and manufacturing sites per target market.
FAQs
1) Are the same suppliers used for bulk ICG and finished injectable ICG?
No. Bulk providers often differ from MAH/distributor networks for finished sterile products, and finished injectable supply depends on sterile manufacturing and regulatory listing.
2) What is the most important document for ICG supplier qualification?
A per-lot Certificate of Analysis (CoA) aligned to the applicable pharmacopoeial or in-house specifications, plus batch traceability and release documentation.
3) What screening item best predicts downstream product performance for ICG?
The assay and impurity/related substance profile and how the supplier controls degradation and variability across lots.
4) Which risk is most common in ICG procurement?
Regional single-source distribution and importer dependency that can tighten lead times when a specific registered product supply is disrupted.
5) Does ICG require special handling for supplier evaluation?
ICG is sensitive to light and solution handling conditions, so suppliers and labels must clearly support storage and reconstitution requirements used by end users.
References
[1] U.S. Food and Drug Administration. Indocyanine Green product and labeling records (accessed via FDA drug databases). https://www.accessdata.fda.gov/
